ENDRA Life Sciences Inc.

The company, incorporated in Delaware in 2007, is developing a next-generation enhanced ultrasound technology platform called Thermo-Acoustic Enhanced Ultrasound (TAEUS®). The initial focus for TAEUS is to assess liver fat, a key indicator for metabolic diseases such as metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). The company aims to create a scalable, non-invasive, point-of-care biomarker solution for metabolic disease assessment and management. To support market adoption, the company is leveraging artificial intelligence and machine learning to improve measurement accuracy and reproducibility, integrating thermo-acoustic technology with conventional ultrasound to streamline workflows and reduce operator variability, and reducing system size and cost to enhance accessibility. The go-to-market strategy targets four markets: Pharmaceutical Companies and Clinical Research Organizations (CROs), High-end Primary Care Networks (Concierge Medicine), Bariatric and Metabolic Clinics, and Primary and Internal Medicine Practices. The company plans to offer a multi-year, subscription-based business model with recurring revenue, alongside traditional capital equipment sales with service and upgrade options. In 2025, the company expanded its business strategy to include a Digital Asset Treasury (DAT) initiative, managed with Arca Investment Management (Arca), which aims to preserve capital and generate non-dilutive returns through investments in decentralized finance (DeFi) assets. This financial strategy complements the company's core mission of commercializing the TAEUS platform through a recurring subscription model, specifically targeting the GLP-1 and metabolic disease markets.